REFERENCES
1. Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:553-64.
2. Duan Y, Xu Y, Dou Y, Xu D. Helicobacter pylori and gastric cancer: mechanisms and new perspectives. J Hematol Oncol. 2025;18:10.
3. Tsay FW, Hsu PI. H. pylori infection and extra-gastroduodenal diseases. J Biomed Sci. 2018;25:65.
4. Yaslianifard S, Sameni F, Kazemi K, et al. Beyond the gut: a comprehensive meta-analysis on Helicobacter pylori infection and cardiovascular complications. Ann Clin Microbiol Antimicrob. 2025;24:18.
5. Penaflorida JLGR, Requesto JRU, Romero KYB, et al. Association between Helicobacter pylori and hepatobiliary cancer: a meta-analysis and systematic review. Asian Pac J Cancer Prev. 2024;25:3363-70.
6. Fabbri N, Greco S, Pesce A, Virgilio F, Romeo D, Feo CV. Role of Helicobacter pylori infection and the risk of cholelithiasis. World J Gastroenterol. 2025;31:102024.
7. Lazarus JV, Colombo M, Cortez-Pinto H, et al. NAFLD - sounding the alarm on a silent epidemic. Nat Rev Gastroenterol Hepatol. 2020;17:377-9.
8. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851-61.
9. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123-33.
10. Guo W, Ge X, Lu J, et al. Diet and risk of non-alcoholic fatty liver disease, cirrhosis, and liver cancer: a large prospective cohort study in UK biobank. Nutrients. 2022;14:5335.
11. Mostafa AM, Pan Z, Yu ML, Örmeci N, Fouad Y, Eslam M. MAFLD: a comprehensive review of the link between metabolic dysfunction and cardiovascular risk. Hepat Med. 2025;17:75-90.
12. Yuan X, Wang X, Wu S, et al. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China. Hepatobiliary Surg Nutr. 2023;12:671-81.
13. Dong TS, Luu K, Lagishetty V, et al. Gut microbiome profiles associated with steatosis severity in metabolic associated fatty liver disease. Hepatoma Res. 2021;7:37.
14. Heydari K, Yousefi M, Alizadeh-Navaei R, et al. Helicobacter pylori infection and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Turk J Gastroenterol. 2022;33:171-81.
15. Gulati A, Roytman M, Lin J, et al. Association between Helicobacter pylori infection, MASLD, and liver fibrosis in patients with severe obesity: a single-center experience. Surg Endosc. 2024;38:6873-9.
16. Liu Y, Xu H, Zhao Z, Dong Y, Wang X, Niu J. No evidence for a causal link between Helicobacter pylori infection and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study. Front Microbiol. 2022;13:1018322.
17. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202-9.
18. Centers for Disease Control and Prevention. NHANES 1999-2000 Laboratory Methods. Available from https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/labmethods.aspx?BeginYear=1999. [accessed 4 June 2026].
19. Centers for Disease Control and Prevention. Questionnaires, Datasets, and Related Documentation-NHANES III. Available from https://wwwn.cdc.gov/nchs/nhanes/nhanes3/datafiles.aspx. [accessed 4 June 2026].
20. Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Manatsathit W, Jaruvongvanich V, Ungprasert P. Helicobacter pylori and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2018;52:386-91.
21. Mantovani A, Turino T, Altomari A, et al. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: an updated meta-analysis. Metabolism. 2019;96:56-65.
22. Xie J, Wang J, Zeng R, Xie Y. Association between Helicobacter pylori infection and triglyceride levels: a nested cross-sectional study. Front Endocrinol. 2023;14:1220347.
23. Zhao MM, Krebs J, Cao X, et al. Helicobacter pylori infection as a risk factor for serum bilirubin change and less favourable lipid profiles: a hospital-based health examination survey. BMC Infect Dis. 2019;19:157.
24. Mansori K, Dehghanbanadaki H, Naderpour S, Rashti R, Moghaddam AB, Moradi Y. A systematic review and meta-analysis of the prevalence of Helicobacter pylori in patients with diabetes. Diabetes Metab Syndr. 2020;14:601-7.
25. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter. 2011;16:79-88.
26. Chen X, Peng R, Peng D, Liu D, Li R. Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study. J Transl Med. 2024;22:701.
27. He C, Yang Z, Cheng D, et al. Helicobacter pylori infection aggravates diet-induced insulin resistance in association with gut microbiota of mice. EBioMedicine. 2016;12:247-54.
28. Candelli M, Franza L, Cianci R, et al. The interplay between Helicobacter pylori and gut microbiota in non-gastrointestinal disorders: a special focus on atherosclerosis. Int J Mol Sci. 2023;24:17520.
29. Yu YY, Tong YL, Wu LY, Yu XY. Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial. Sci Rep. 2022;12:19530.
30. Jamali R, Mofid A, Vahedi H, Farzaneh R, Dowlatshahi S. The effect of Helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial. Hepat Mon. 2013;13:e14679.
31. Kamboj AK, Cotter TG, Oxentenko AS. Helicobacter pylori: the past, present, and future in management. Mayo Clin Proc. 2017;92:599-604.
